NALIRIFOX+Adebrelimab+PULSAR for Advanced Pancreatic Cancer

This study aims to evaluate the safety and preliminary efficacy of NALIRIFOX combined with adebrelimab and PULSAR as first-line treatment for locally advanced unresectable or metastatic pancreatic ductal adenocarcinoma (PDAC). Additionally, it will explore potential predictive and efficacy-related biomarkers.

Trial Details

NCT ID

NCT07595172

Phase

PHASE1 / PHASE2

Sponsor

West China Hospital

Status

RECRUITING

Cancer Type

Pancreatic Cancer

Interventions

NALIRIFOX+Adebrelimab
PULSAR

Locations (sample)

Chengdu, Sichuan, China|30.66667,104.06667

Key Eligibility Criteria

Age: 18-75 years, regardless of gender.
Histologically confirmed pancreatic ductal adenocarcinoma (PDAC).
Previously untreated, locally advanced unresectable or metastatic PDAC, with at least one measurable lesion (RECIST v1.1) not previously irradiated.
ECOG Performance Status (PS): 0-1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →